|
1
|
McLeod HL: Therapeutic drug monitoring
opportunities in cancer therapy. Pharmacol Ther. 74:39–54. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu H, Steeghs N, Nijenhuis CM, Schellens
JH, Beijnen JH and Huitema AD: Practical guidelines for therapeutic
drug monitoring of anticancer tyrosine kinase inhibitors: Focus on
the pharmacokinetic targets. Clin Pharmacokinet. 53:305–325. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Jonge ME, Huitema AD, Schellens JH,
Rodenhuis S and Beijnen JH: Individualised cancer chemotherapy:
Strategies and performance of prospective studies on therapeutic
drug monitoring with dose adaptation: A review. Clin Pharmacokinet.
44:147–173. 2012. View Article : Google Scholar
|
|
4
|
Mathijssen RH, de Jong FA, Loos WJ, van
der Bol JM, Verweij J and Sparreboom A: Flat-fixed dosing versus
body surface area based dosing of anticancer drugs in adults: Does
it make a difference? Oncologist. 12:913–923. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arora A and Scholar EM: Role of tyrosine
kinase inhibitors in cancer therapy. J Pharmacol Exp Ther.
315:971–979. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Josephs DH, Fisher DS, Spicer J and
Flanagan RJ: Clinical pharmacokinetics of tyrosine kinase
inhibitors: Implications for therapeutic drug monitoring. Ther Drug
Monit. 35:562–587. 2013.PubMed/NCBI
|
|
7
|
Widmer N, Bardin C, Chatelut E, Paci A,
Beijnen J, Levêque D, Veal G and Astier A: Review of therapeutic
drug monitoring of anticancer drugs part two - targeted therapies.
Eur J Cancer. 50:2020–2036. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Erp NP, Gelderblom H and Guchelaar HJ:
Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer
Treat Rev. 35:692–706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Teo YL, Ho HK and Chan A:
Metabolism-related pharmacokinetic drug-drug interactions with
tyrosine kinase inhibitors: Current understanding, challenges and
recommendations. Br J Clin Pharmacol. 79:241–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Apperley JF: Part II: Management of
resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol.
8:1116–1128. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giles FJ, le Coutre PD, Pinilla-Ibarz J,
Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio
G, Hughes TP, et al: Nilotinib in imatinib-resistant or
imatinib-intolerant patients with chronic myeloid leukemia in
chronic phase: 48-month follow-up results of a phase II study.
Leukemia. 27:107–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hochhaus A, Kantarjian HM, Baccarani M,
Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes
F, Niederwieser D, et al: Dasatinib induces notable hematologic and
cytogenetic responses in chronic-phase chronic myeloid leukemia
after failure of imatinib therapy. Blood. 109:2303–2309. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brave M, Goodman V, Kaminskas E, Farrell
A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J,
et al: Sprycel for chronic myeloid leukemia and Philadelphia
chromosome-positive acute lymphoblastic leukemia resistant to or
intolerant of imatinib mesylate. Clin Cancer Res. 14:352–359. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mathisen MS, Kantarjian HM, Cortes J and
Jabbour EJ: Practical issues surrounding the explosion of tyrosine
kinase inhibitors for the management of chronic myeloid leukemia.
Blood Rev. 28:179–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cortes JE, Kantarjian HM, Brümmendorf TH,
Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S,
Volkert A, et al: Safety and efficacy of bosutinib (SKI-606) in
chronic phase Philadelphia chromosome-positive chronic myeloid
leukemia patients with resistance or intolerance to imatinib
(erratum). Blood. 122:25242013.
|
|
16
|
Motzer RJ, Michaelson MD, Redman BG, Hudes
GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE,
et al: Activity of SU11248, a multitargeted inhibitor of vascular
endothelial growth factor receptor and platelet-derived growth
factor receptor, in patients with metastatic renal cell carcinoma.
J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haouala A, Zanolari B, Rochat B,
Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N and
Decosterd LA: Therapeutic drug monitoring of the new targeted
anticancer agents imatinib, nilotinib, dasatinib, sunitinib,
sorafenib and lapatinib by LC tandem mass spectrometry. J
Chromatogr B Analyt Technol Biomed Life Sci. 877:1982–1996. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pirro E, De Francia S, De Martino F, Fava
C, Ulisciani S, Cambrin GR, Racca S, Saglio G and Di Carlo F: A new
HPLC-UV validated method for therapeutic drug monitoring of
tyrosine kinase inhibitors in leukemic patients. J Chromatogr Sci.
49:753–757. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saita T, Shin M and Fujito H: Development
of a specific and sensitive enzyme-linked immunosorbent assay for
the quantification of imatinib. Biol Pharm Bull. 36:1964–1968.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Götze L, Hegele A, Metzelder SK, Renz H
and Nockher WA: Development and clinical application of a LC-MS/MS
method for simultaneous determination of various tyrosine kinase
inhibitors in human plasma. Clin Chim Acta. 413:143–149. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ajimura TO, Borges KB, Ferreira AF, de
Castro FA and de Gaitani CM: Capillary electrophoresis method for
plasmatic determination of imatinib mesylate in chronic myeloid
leukemia patients. Electrophoresis. 32:1885–1892. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rezende VM, Rivellis AJ, Gomes MM, Dörr
FA, Novaes MM, Nardinelli L, Costa AL, Chamone DA and Bendit I:
Determination of serum levels of imatinib mesylate in patients with
chronic myeloid leukemia: Validation and application of a new
analytical method to monitor treatment compliance. Rev Bras Hematol
Hemoter. 35:103–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roth O, Spreux-Varoquaux O, Bouchet S,
Rousselot P, Castaigne S, Rigaudeau S, Raggueneau V, Therond P,
Devillier P, Molimard M and Maneglier B: Imatinib assay by HPLC
with photodiode-array UV detection in plasma from patients with
chronic myeloid leukemia: Comparison with LC-MS/MS. Clin Chim Acta.
411:140–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Widmer N, Béguin A, Rochat B, Buclin T,
Kovacsovics T, Duchosal MA, Leyvraz S, Rosselet A, Biollaz J and
Decosterd LA: Determination of imatinib (Gleevec) in human plasma
by solid-phase extraction-liquid chromatography-ultraviolet
absorbance detection. J Chromatogr B Analyt Technol Biomed Life
Sci. 803:285–292. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Velpandian T, Mathur R, Agarwal NK, Arora
B, Kumar L and Gupta SK: Development and validation of a simple
liquid chromatographic method with ultraviolet detection for the
determination of imatinib in biological samples. J Chromatogr B
Analyt Technol Biomed Life Sci. 804:431–434. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bende G, Kollipara S, Movva S, Moorthy G
and Saha R: Validation of an HPLC method for determination of
imatinib mesylate in rat serum and its application in a
pharmacokinetic study. J Chromatogr Sci. 48:334–341. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pursche S, Ottmann OG, Ehninger G and
Schleyer E: High-performance liquid chromatography method with
ultraviolet detection for the quantification of the BCR-ABL
inhibitor nilotinib (AMN107) in plasma, urine, culture medium and
cell preparations. J Chromatogr B Analyt Technol Biomed Life Sci.
852:208–216. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miura M, Takahashi N and Sawada K:
High-performance liquid chromatography with solid-phase extraction
for the quantitative determination of nilotinib in human plasma.
Biomed Chromatogr. 24:789–793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yuki M, Yamakawa Y, Uchida T, Nambu T,
Kawaguchi T, Hamada A and Saito H: High-performance liquid
chromatographic assay for the determination of nilotinib in human
plasma. Biol Pharm Bull. 34:1126–1128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Davies A, Hayes AK, Knight K, Watmough SJ,
Pirmohamed M and Clark RE: Simultaneous determination of nilotinib,
imatinib and its main metabolite (CGP-74588) in human plasma by
ultra-violet high performance liquid chromatography. Leuk Res.
34:702–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Faivre L, Gomo C, Mir O, Taieb F,
Schoemann-Thomas A, Ropert S, Vidal M, Dusser D, Dauphin A,
Goldwasser F and Blanchet B: A simple HPLC-UV method for the
simultaneous quantification of gefitinib and erlotinib in human
plasma. J Chromatogr B Analyt Technol Biomed Life Sci.
879:2345–2350. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Afify S, Rapp UR and Högger P: Validation
of a liquid chromatography assay for the quantification of the Raf
kinase inhibitor BAY 43–9006 in small volumes of mouse serum. J
Chromatogr B Analyt Technol Biomed Life Sci. 809:99–103. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Blanchet B, Billemont B, Cramard J,
Benichou AS, Chhun S, Harcouet L, Ropert S, Dauphin A, Goldwasser F
and Tod M: Validation of an HPLC-UV method for sorafenib
determination in human plasma and application to cancer patients in
routine clinical practice. J Pharm Biomed Anal. 49:1109–1114. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blanchet B, Saboureau C, Benichou AS,
Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F and Tod M:
Development and validation of an HPLC-UV-visible method for
sunitinib quantification in human plasma. Clin Chim Acta.
404:134–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhen Y, Thomas-Schoemann A, Sakji L,
Boudou-Rouquette P, Dupin N, Mortier L, Vidal M, Goldwasser F and
Blanchet B: An HPLC-UV method for the simultaneous quantification
of vemurafenib and erlotinib in plasma from cancer patients. J
Chromatogr B Analyt Technol Biomed Life Sci. 928:93–97. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jones HK, Stafford LE, Swaisland HC and
Payne R: A sensitive assay for ZD1839 (Iressa) in human plasma by
liquid-liquid extraction and high performance liquid chromatography
with mass spectrometric detection: Validation and use in Phase I
clinical trials. J Pharm Biomed Anal. 29:221–228. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rezende VM, Rivellis A, Novaes MM, de
Alencar Fisher, Chamone D and Bendit I: Quantification of imatinib
in human serum: Validation of a high-performance liquid
chromatography-mass spectrometry method for therapeutic drug
monitoring and pharmacokinetic assays. Drug Des Devel Ther.
7:699–710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
De Francia S, D'Avolio A, De Martino F,
Pirro E, Baietto L, Siccardi M, Simiele M, Racca S, Saglio G, Di
Carlo F and Di Perri G: New HPLC-MS method for the simultaneous
quantification of the antileukemia drugs imatinib, dasatinib, and
nilotinib in human plasma. J Chromatogr B Analyt Technol Biomed
Life Sci. 877:1721–1726. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sparidans RW, Iusuf D, Schinkel AH,
Schellens JH and Beijnen JH: Liquid chromatography-tandem mass
spectrometric assay for the light sensitive tyrosine kinase
inhibitor axitinib in human plasma. J Chromatogr B Analyt Technol
Biomed Life Sci. 877:4090–4096. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Furlong MT, Agrawal S, Hawthorne D, Lago
M, Unger S, Krueger L and Stouffer B: A validated LC-MS/MS assay
for the simultaneous determination of the anti-leukemic agent
dasatinib and two pharmacologically active metabolites in human
plasma: Application to a clinical pharmacokinetic study. J Pharm
Biomed Anal. 58:130–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhao M, He P, Rudek MA, Hidalgo M and
Baker SD: Specific method for determination of OSI-774 and its
metabolite OSI-420 in human plasma by using liquid
chromatography-tandem mass spectrometry. J Chromatogr B Analyt
Technol Biomed Life Sci. 793:413–420. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Masters AR, Sweeney CJ and Jones DR: The
quantification of erlotinib (OSI-774) and OSI-420 in human plasma
by liquid chromatography-tandem mass spectrometry. J Chromatogr B
Analyt Technol Biomed Life Sci. 848:379–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Thappali SR, Varanasi K, Veeraraghavan S,
Arla R, Chennupati S, Rajamanickam M, Vakkalanka S and Khagga M:
Simultaneous determination of celecoxib, erlotinib, and its
metabolite desmethyl-erlotinib (OSI-420) in rat plasma by liquid
chromatography/tandem mass spectrometry with positive/negative
ion-switching electrospray ionisation. Sci Pharm. 80:633–646. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang LZ, Lim MY, Chin TM, Thuya WL, Nye
PL, Wong A, Chan SY, Goh BC and Ho PC: Rapid determination of
gefitinib and its main metabolite, O-desmethyl gefitinib in human
plasma using liquid chromatography-tandem mass spectrometry. J
Chromatogr B Analyt Technol Biomed Life Sci. 879:2155–2161. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Moreno JM, Wojnicz A, Steegman JL,
Cano-Abad MF and Ruiz-Nuño A: Imatinib assay by high-performance
liquid chromatography in tandem mass spectrometry with solid-phase
extraction in human plasma. Biomed Chromatogr. 27:502–508. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Titier K, Picard S, Ducint D, Teilhet E,
Moore N, Berthaud P, Mahon FX and Molimard M: Quantification of
imatinib in human plasma by high-performance liquid
chromatography-tandem mass spectrometry. Ther Drug Monit.
27:634–640. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bianchi F, Caffarri E, Cavalli S, Lagrasta
C, Musci M, Quaini F and Savi M: Development and validation of an
high performance liquid chromatography-tandem mass spectrometry
method for the determination of imatinib in rat tissues. J Pharm
Biomed Anal. 73:103–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bakhtiar R, Khemani L, Hayes M, Bedman T
and Tse F: Quantification of the anti-leukemia drug STI571
(Gleevec) and its metabolite (CGP 74588) in monkey plasma using a
semi-automated solid phase extraction procedure and liquid
chromatography-tandem mass spectrometry. J Pharm Biomed Anal.
28:1183–1194. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bakhtiar R, Lohne J, Ramos L, Khemani L,
Hayes M and Tse F: High-throughput quantification of the
anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP
74588) in human plasma using liquid chromatography-tandem mass
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci.
768:325–340. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Parise RA, Ramanathan RK, Hayes MJ and
Egorin MJ: Liquid chromatographic-mass spectrometric assay for
quantitation of imatinib and its main metabolite (CGP 74588) in
plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 791:39–44.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bai F, Freeman BB III, Fraga CH, Fouladi M
and Stewart CF: Determination of lapatinib (GW572016) in human
plasma by liquid chromatography electrospray tandem mass
spectrometry (LC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed
Life Sci. 831:169–175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Minocha M, Khurana V and Mitra AK:
Determination of pazopanib (GW-786034) in mouse plasma and brain
tissue by liquid chromatography-tandem mass spectrometry
(LC/MS-MS). J Chromatogr B Analyt Technol Biomed Life Sci.
901:85–92. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Minkin P, Zhao M, Chen Z, Ouwerkerk J,
Gelderblom H and Baker SD: Quantification of sunitinib in human
plasma by high-performance liquid chromatography-tandem mass
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci.
874:84–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhou Q and Gallo JM: Quantification of
sunitinib in mouse plasma, brain tumor and normal brain using
liquid chromatography-electrospray ionization-tandem mass
spectrometry and pharmacokinetic application. J Pharm Biomed Anal.
51:958–964. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Oberoi RK, Mittapalli RK, Fisher J and
Elmquist WF: Sunitinib LC-MS/MS assay in mouse plasma and brain
tissue: Application in CNS distribution studies. Chromatographia.
76:762013. View Article : Google Scholar
|
|
56
|
Luethi D, Durmus S, Schinkel AH, Schellens
JH, Beijnen JH and Sparidans RW: Liquid chromatography-tandem mass
spectrometric assay for the multikinase inhibitor regorafenib in
plasma. Biomed Chromatogr. 28:1366–1370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Alvarez JC, Funck-Brentano E, Abe E,
Etting I, Saiag P and Knapp A: A LC/MS/MS micro-method for human
plasma quantification of vemurafenib. Application to treated
melanoma patients. J Pharm Biomed Anal. 97:29–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Nijenhuis CM, Rosing H, Schellens JH and
Beijnen JH: Development and validation of a high-performance liquid
chromatography-tandem mass spectrometry assay quantifying
vemurafenib in human plasma. J Pharm Biomed Anal. 88:630–635. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Honeywell R, Yarzadah K, Giovannetti E,
Losekoot N, Smit EF, Walraven M, Lind JS, Tibaldi C, Verheul HM and
Peters GJ: Simple and selective method for the determination of
various tyrosine kinase inhibitors used in the clinical setting by
liquid chromatography tandem mass spectrometry. J Chromatogr B
Analyt Technol Biomed Life Sci. 878:1059–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lankheet NA, Blank CU, Mallo H, Adriaansz
S, Rosing H, Schellens JH, Huitema AD and Beijnen JH: Determination
of sunitinib and its active metabolite N-desethylsunitinib in sweat
of a patient. J Anal Toxicol. 35:558–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Couchman L, Birch M, Ireland R, Corrigan
A, Wickramasinghe S, Josephs D, Spicer J and Flanagan RJ: An
automated method for the measurement of a range of tyrosine kinase
inhibitors in human plasma or serum using turbulent flow liquid
chromatography-tandem mass spectrometry. Anal Bioanal Chem.
403:1685–1695. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Veeraraghavan S, Thappali S, Viswanadha S,
Chennupati S, Nalla S, Golla M, Vakkalanka S and Rangasamy M:
Simultaneous quantification of ruxolitinib and nilotinib in rat
plasma by LC-MS/MS: Application to a pharmacokinetic study. J Pharm
Biomed Anal. 94:125–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
de Bruijn P, Sleijfer S, Lam MH,
Mathijssen RH, Wiemer EA and Loos WJ: Bioanalytical method for the
quantification of sunitinib and its N-desethyl metabolite SU12662
in human plasma by ultra performance liquid chromatography/tandem
triple-quadrupole mass spectrometry. J Pharm Biomed Anal.
51:934–941. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bihan K, Sauzay C, Goldwirt L,
Charbonnier-Beaupel F, Hulot JS, Funck-Brentano C and Zahr N:
Development and validation of a rapid and simple LC-MS/MS method
for quantification of vemurafenib in human plasma: Application to a
human pharmacokinetic study. Ther Drug Monit. 37:132–136. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bouchet S, Chauzit E, Ducint D, Castaing
N, Canal-Raffin M, Moore N, Titier K and Molimard M: Simultaneous
determination of nine tyrosine kinase inhibitors by 96-well
solid-phase extraction and ultra performance LC/MS-MS. Clin Chim
Acta. 412:1060–1067. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
van Erp NP, de Wit D, Guchelaar HJ,
Gelderblom H, Hessing TJ and Hartigh J: A validated assay for the
simultaneous quantification of six tyrosine kinase inhibitors and
two active metabolites in human serum using liquid chromatography
coupled with tandem mass spectrometry. J Chromatogr B Analyt
Technol Biomed Life Sci. 937:33–43. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Martins DH, Wagner SC, Dos Santos TV,
Lizot LL, Antunes MV, Capra M and Linden R: Monitoring imatinib
plasma concentrations in chronic myeloid leukemia. Rev Bras Hematol
Hemoter. 33:302–306. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Haura EB, Tanvetyanon T, Chiappori A,
Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L,
Neuger A, et al: Phase I//II study of the Src inhibitor dasatinib
in combination with erlotinib in advanced non-small cell lung
cancer. J Clin Oncol. 28:1387–1394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Osterberg L and Blaschke T: Adherence to
medication. N Engl J Med. 353:487–497. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Marin D, Bazeos A, Mahon FX, Eliasson L,
Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K,
et al: Adherence is the critical factor for achieving molecular
responses in patients with chronic myeloid leukemia who achieve
complete cytogenetic responses on imatinib. J Clin Oncol.
28:2381–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Klümpen HJ, Samer CF, Mathijssen RH,
Schellens JH and Gurney H: Moving towards dose individualization of
tyrosine kinase inhibitors. Cancer Treat Rev. 37:251–260. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Opdam FL, Gelderblom H and Guchelaar HJ:
Phenotyping drug disposition in oncology. Cancer Treat Rev.
38:715–725. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Pajares B, Torres E, Trigo JM, Sáez MI,
Ribelles N, Jiménez B and Alba E: Tyrosine kinase inhibitors and
drug interactions: A review with practical recommendations. Clin
Transl Oncol. 14:94–101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Larson RA, Druker BJ, Guilhot F, O'Brien
SG, Riviere GJ, Krahnke T, Gathmann I and Wang Y: IRIS
(International Randomized Interferon vs STI571) Study Group:
Imatinib pharmacokinetics and its correlation with response and
safety in chronic-phase chronic myeloid leukemia: A subanalysis of
the IRIS study. Blood. 111:4022–4028. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Peng B, Hayes M, Resta D, Racine-Poon A,
Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P and
Capdeville R: Pharmacokinetics and pharmacodynamics of imatinib in
a phase I trial with chronic myeloid leukemia patients. J Clin
Oncol. 22:935–942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Picard S, Titier K, Etienne G, Teilhet E,
Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, et
al: Trough imatinib plasma levels are associated with both
cytogenetic and molecular responses to standard-dose imatinib in
chronic myeloid leukemia. Blood. 109:3496–3499. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Awidi A, Ayed AO, Bsoul N, Magablah A,
Mefleh R, Dweiri M, Ramahi M, Arafat E, Bishtawi M and Marie L:
Relationship of serum imatinib trough level and response in CML
patients: Long term follow-up. Leuk Res. 34:1573–1575. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Kawaguchi T, Hamada A, Hirayama C,
Nakashima R, Nambu T, Yamakawa Y, Watanabe H, Horikawa K, Mitsuya H
and Saito H: Relationship between an effective dose of imatinib,
body surface area, and trough drug levels in patients with chronic
myeloid leukemia. Int J Hematol. 89:642–648. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Demetri GD, Wang Y, Wehrle E, Racine A,
Nikolova Z, Blanke CD, Joensuu H and von Mehren M: Imatinib plasma
levels are correlated with clinical benefit in patients with
unresectable/metastatic gastrointestinal stromal tumors. J Clin
Oncol. 27:3141–3147. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Delbaldo C, Chatelut E, Ré M, Deroussent
A, Séronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY and
Vassal G: Pharmacokinetic-pharmacodynamic relationships of imatinib
and its main metabolite in patients with advanced gastrointestinal
stromal tumors. Clin Cancer Res. 12:6073–6078. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yoon S, Ryu MH, Yoo C, Beck MY, Ryoo BY
and Kang YK: Imatinib plasma monitoring-guided dose modification
for managing imatinib-related toxicities in gastrointestinal
stromal tumor patients. J Korean Med Sci. 28:1248–1252. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Baccarani M and Dreyling M: ESMO
Guidelines Working Group: Chronic myelogenous leukemia: ESMO
clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 20(Suppl 4): S105–S107. 2009.
|
|
83
|
Gotta V, Widmer N, Decosterd LA, Chalandon
Y, Heim D, Gregor M, Benz R, Leoncini-Franscini L, Baerlocher GM,
Duchosal MA, et al: Clinical usefulness of therapeutic
concentration monitoring for imatinib dosage individualization:
Results from a randomized controlled trial. Cancer Chemother
Pharmacol. 74:1307–1319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Deininger MW: Milestones and monitoring in
patients with CML treated with imatinib. Hematology Am Soc Hematol
Educ Program. 2008:419–426. 2008.
|
|
85
|
Kantarjian H, Giles F, Wunderle L, Bhalla
K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W,
et al: Nilotinib in imatinib-resistant CML and Philadelphia
chromosome-positive ALL. N Engl J Med. 354:2542–2551. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wang X, Roy A, Hochhaus A, Kantarjian HM,
Chen TT and Shah NP: Differential effects of dosing regimen on the
safety and efficacy of dasatinib: Retrospective exposure-response
analysis of a phase III study. Clin Pharmacol. 5:85–97.
2013.PubMed/NCBI
|
|
87
|
Larson RA, Yin OQ, Hochhaus A, Saglio G,
Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP,
Kantarjian HM and le Coutre PD: Population pharmacokinetic and
exposure-response analysis of nilotinib in patients with newly
diagnosed Ph+ chronic myeloid leukemia in chronic phase.
Eur J Clin Pharmacol. 68:723–733. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Nakamura Y, Sano K, Soda H, Takatani H,
Fukuda M, Nagashima S, Hayashi T, Oka M, Tsukamoto K and Kohno S:
Pharmacokinetics of gefitinib predicts antitumor activity for
advanced non-small cell lung cancer. J Thorac Oncol. 5:1404–1409.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhao YY, Li S, Zhang Y, Zhao HY, Liao H,
Guo Y, Shi YX, Jiang W, Xue C and Zhang L: The relationship between
drug exposure and clinical outcomes of non-small cell lung cancer
patients treated with gefitinib. Med Oncol. 28:697–702. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Faivre S, Delbaldo C, Vera K, Robert C,
Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, et
al: Safety, pharmacokinetic, and antitumor activity of SU11248, a
novel oral multitarget tyrosine kinase inhibitor, in patients with
cancer. J Clin Oncol. 24:25–35. 2006. View Article : Google Scholar : PubMed/NCBI
|
